• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HuR、COX-2 和 survivin 在肺癌中的表达;细胞质 HuR 稳定鳞状细胞癌中的环氧化酶-2。

Expression of HuR, COX-2, and survivin in lung cancers; cytoplasmic HuR stabilizes cyclooxygenase-2 in squamous cell carcinomas.

机构信息

Department of Pathology, Kyung Hee University Hospital at Gangdong, School of Medicine, Kyung Hee University, Seoul, South Korea.

出版信息

Mod Pathol. 2011 Oct;24(10):1336-47. doi: 10.1038/modpathol.2011.90. Epub 2011 May 13.

DOI:10.1038/modpathol.2011.90
PMID:21572400
Abstract

Hu antigen R (HuR) is a member of the human family of embryonic-lethal, abnormal vision-like proteins, which serves as an mRNA-binding protein. In the cytoplasm, HuR can stabilize the mRNA of cyclooxygenase-2 (COX-2), an enzyme that catalyses the synthesis of prostaglandins and is associated with promotion of carcinogenesis and tumor cell resistance to apoptosis. Intracellular (cytoplasmic and nuclear) localization of survivin has a prognostic significance as an apoptosis inhibitor and a regulator of cell division in tumors. Patients with 151 squamous cell carcinomas and 93 adenocarcinomas underwent lobectomy or pneumonectomy with hilar and mediastinal lymph node sampling. Paraffin-embedded tumor sections were retrieved for evaluation of nuclear and cytoplasmic staining of survivin and HuR, and cytoplasmic staining of COX-2. In squamous cell carcinomas, COX-2 expression was correlated with a difference of survivin (cytoplasmic-nuclear; P=0.004), cytoplasmic HuR (P=0.018), total HuR (cytoplasmic+nuclear; P=0.009), and difference of HuR (P=0.020). COX-2 was inversely correlated with nuclear survivin (P=0.006). In a univariate analysis by log-rank test, survival was associated with cytoplasmic survivin (adenocarcinoma, P<0.001; squamous cell carcinoma, P=0.005), difference of survivin (adenocarcinoma, P<0.001; squamous cell carcinoma, P=0.014), and COX-2 (squamous cell carcinoma, P=0.001). Survival was inversely associated with nuclear survivin (adenocarcinoma, P=0.006, squamous cell carcinoma, P=0.014). In a multivariate survival analysis, cytoplasmic survivin (adenocarcinoma, P=0.002; squamous cell carcinoma, P=0.015) and COX-2 (squamous cell carcinoma, P=0.020) were determined as independent prognostic factors. Cytoplasmic HuR expression is associated with COX-2 expression in squamous cell carcinomas. The expression of COX-2 in squamous cell carcinomas, and cytoplasmic survivin in adenocarcinomas and squamous cell carcinomas could be useful independent prognostic markers.

摘要

Hu 抗原 R(HuR)是人类胚胎致死性、异常视觉样蛋白家族的成员,作为一种 mRNA 结合蛋白。在细胞质中,HuR 可以稳定环氧化酶-2(COX-2)的 mRNA,COX-2 是一种催化前列腺素合成的酶,与促进致癌作用和肿瘤细胞对凋亡的抵抗力有关。存活素的细胞内(细胞质和核)定位作为凋亡抑制剂和肿瘤细胞分裂的调节剂具有预后意义。对 151 例鳞状细胞癌和 93 例腺癌患者进行了肺叶切除术或全肺切除术,并进行了肺门和纵隔淋巴结取样。检索石蜡包埋的肿瘤切片,以评估核和细胞质中存活素和 HuR 的染色,以及细胞质中 COX-2 的染色。在鳞状细胞癌中,COX-2 表达与存活素(细胞质-核;P=0.004)、细胞质 HuR(P=0.018)、总 HuR(细胞质+核;P=0.009)和 HuR 差异(P=0.020)有关。COX-2 与核存活素呈负相关(P=0.006)。通过对数秩检验的单因素分析,生存与细胞质存活素(腺癌,P<0.001;鳞状细胞癌,P=0.005)、存活素差异(腺癌,P<0.001;鳞状细胞癌,P=0.014)和 COX-2(鳞状细胞癌,P=0.001)有关。生存与核存活素呈负相关(腺癌,P=0.006,鳞状细胞癌,P=0.014)。在多因素生存分析中,细胞质存活素(腺癌,P=0.002;鳞状细胞癌,P=0.015)和 COX-2(鳞状细胞癌,P=0.020)被确定为独立的预后因素。在鳞状细胞癌中,细胞质 HuR 表达与 COX-2 表达相关。COX-2 在鳞状细胞癌中的表达,以及在腺癌和鳞状细胞癌中的细胞质存活素,可以作为有用的独立预后标志物。

相似文献

1
Expression of HuR, COX-2, and survivin in lung cancers; cytoplasmic HuR stabilizes cyclooxygenase-2 in squamous cell carcinomas.HuR、COX-2 和 survivin 在肺癌中的表达;细胞质 HuR 稳定鳞状细胞癌中的环氧化酶-2。
Mod Pathol. 2011 Oct;24(10):1336-47. doi: 10.1038/modpathol.2011.90. Epub 2011 May 13.
2
Correlation between survivin expression and prognosis in non-small cell lung cancer.非小细胞肺癌中生存素表达与预后的相关性
Respir Med. 2006 Dec;100(12):2220-6. doi: 10.1016/j.rmed.2006.02.031. Epub 2006 May 2.
3
Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression.胚胎致死性异常视觉样蛋白HuR在卵巢癌中的过表达是一个预后因素,且与环氧化酶2表达增加有关。
Cancer Res. 2004 Jan 1;64(1):189-95. doi: 10.1158/0008-5472.can-03-1987.
4
Expression of HuR is associated with increased cyclooxygenase-2 expression in uterine cervical carcinoma.HuR的表达与子宫颈癌中环氧合酶-2表达的增加相关。
Int J Gynecol Pathol. 2007 Jul;26(3):229-34. doi: 10.1097/01.pgp.0000236946.82334.07.
5
Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.CD73和A2A腺苷受体表达对非小细胞肺癌的预后影响
Oncotarget. 2017 Jan 31;8(5):8738-8751. doi: 10.18632/oncotarget.14434.
6
Cytoplasmic HuR over-expression is associated with increased cyclooxygenase-2 expression in laryngeal squamous cell carcinomas.在喉鳞状细胞癌中,细胞质HuR过表达与环氧化酶-2表达增加有关。
Pathology. 2007 Dec;39(6):545-50. doi: 10.1080/00313020701684391.
7
Immunohistochemical expression of nuclear and cytoplasmic survivin in gastrointestinal carcinoma.胃肠道癌中核及胞质生存素的免疫组化表达
Int J Clin Exp Pathol. 2013 Nov 15;6(12):2919-27. eCollection 2013.
8
Association between expression of embryonic lethal abnormal vision-like protein HuR and cyclooxygenase-2 in oral squamous cell carcinoma.胚胎致死异常视觉样蛋白 HuR 表达与口腔鳞状细胞癌中环氧化酶-2 的关系。
Head Neck. 2011 May;33(5):627-37. doi: 10.1002/hed.21507. Epub 2010 Oct 19.
9
Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human non-small-cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.人非小细胞肺癌中Hu抗原受体(HuR)和环氧化酶-2(COX-2)的表达:与临床病理参数、肿瘤增殖能力及患者生存的关系
Tumour Biol. 2015 Jan;36(1):315-27. doi: 10.1007/s13277-014-2637-y. Epub 2014 Sep 25.
10
Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer.HAb18G/CD147 的表达及其定位与非小细胞肺癌的进展和不良预后相关。
Pathol Res Pract. 2013 Jun;209(6):345-52. doi: 10.1016/j.prp.2013.02.015. Epub 2013 Mar 25.

引用本文的文献

1
HuR-dependent SOD2 protein synthesis is an early adaptation to anchorage-independence.HuR依赖的超氧化物歧化酶2(SOD2)蛋白合成是对锚定非依赖性的早期适应性反应。
Redox Biol. 2022 Jul;53:102329. doi: 10.1016/j.redox.2022.102329. Epub 2022 May 13.
2
Drug delivery approaches for HuR-targeted therapy for lung cancer.用于肺癌的 HuR 靶向治疗的药物递送方法。
Adv Drug Deliv Rev. 2022 Jan;180:114068. doi: 10.1016/j.addr.2021.114068. Epub 2021 Nov 22.
3
HuR enhances FSTL1 transcript stability to promote invasion and metastasis of squamous cell carcinoma.
HuR增强FSTL1转录本稳定性以促进鳞状细胞癌的侵袭和转移。
Am J Cancer Res. 2021 Oct 15;11(10):4981-4993. eCollection 2021.
4
Clinicopathological and Prognostic Significance of Inhibitor of Apoptosis Protein (IAP) Family Members in Lung Cancer: A Meta-Analysis.肺癌中凋亡抑制蛋白(IAP)家族成员的临床病理及预后意义:一项荟萃分析
Cancers (Basel). 2021 Aug 14;13(16):4098. doi: 10.3390/cancers13164098.
5
Understanding the molecular association between hyperkalemia and lung squamous cell carcinomas.理解高钾血症与肺鳞癌之间的分子关联。
BMC Med Genet. 2020 Oct 22;21(Suppl 1):176. doi: 10.1186/s12881-020-01099-7.
6
Quantification and Localization of Protein-RNA Interactions in Patient-Derived Archival Tumor Tissue.在患者来源的存档肿瘤组织中定量和定位蛋白-RNA 相互作用。
Cancer Res. 2019 Oct 15;79(20):5418-5431. doi: 10.1158/0008-5472.CAN-19-1094. Epub 2019 Sep 3.
7
Human antigen R mediated post-transcriptional regulation of inhibitors of apoptosis proteins in pancreatic cancer.人抗原 R 介导的胰腺癌中凋亡蛋白抑制剂的转录后调控。
World J Gastroenterol. 2019 Jan 14;25(2):205-219. doi: 10.3748/wjg.v25.i2.205.
8
Expression analysis of cyclooxygenase-2 in patients suffering from esophageal squamous cell carcinoma.环氧化酶-2 在食管鳞状细胞癌患者中的表达分析。
PLoS One. 2018 Oct 19;13(10):e0205508. doi: 10.1371/journal.pone.0205508. eCollection 2018.
9
miR-291b-3p mediated ROS-induced endothelial cell dysfunction by targeting HUR.miR-291b-3p 通过靶向 HUR 介导 ROS 诱导的内皮细胞功能障碍。
Int J Mol Med. 2018 Nov;42(5):2383-2392. doi: 10.3892/ijmm.2018.3821. Epub 2018 Aug 10.
10
Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development.癌症中的翻译失调:分子见解及其在生物标志物开发中的潜在临床应用
Front Oncol. 2017 Jul 26;7:158. doi: 10.3389/fonc.2017.00158. eCollection 2017.